Michael Kitt, M.D.
Chief Executive Officer

Dr. Kitt joined Attenua as Chief Executive Officer in April 2018, bringing more than 30 years of clinical development experience and industry expertise. Prior to joining Attenua he developed AF-219, a P2X3 antagonist for the treatment of cough at Afferent Pharmaceuticals, Inc as Chief Medical Officer. Prior to that Dr. Kitt served as Senior Vice President and Chief Medical Officer at Portola Pharmaceuticals, Executive Vice President and Chief Medical Officer of Nuon Therapeutics, Inc. From March 2002 to September 2008, he served as Senior Vice President of Development at Theravance, Inc. He has also held various executive positions at several pharmaceutical companies, including COR Therapeutics, Sterling-Winthrop, Inc. and The Upjohn Company. Dr. Kitt received his M.D. degree from NYU School of Medicine and B.S. in Biochemistry from NYU School of Engineering.

Peter G. Butera
Vice President, Clinical Operations

Mr. Butera joined Attenua in April 2018 as VP, Clinical Operations, bringing more than 30 years of diverse clinical experience, from CROs and large pharma to start-up companies. Mr. Butera was previously Vice President, Clinical Operations at Afferent, where he ran clinical programs in chronic pain and cough, until its $1.25 billion acquisition by Merck & Co. in 2016. Prior to Afferent, Mr. Butera spent 10 years at Pain Therapeutics serving as director and vice president, clinical operations. In this role, he managed clinical development programs for chronic pain compounds in both early and late stage development. Mr. Butera has a B.S. degree from Saint Joseph’s University.